Go to content
MDxHealth

MDxHealth

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 12 nov 2008 - 10:10
Statutaire naam MDxHealth
Titel OncoMethylome Sciences licenses methylation technologies to Qiagen for commercializing epigenetic applications for the scientific research market
Bericht Liège, Belgium – November 12, 2008, 08.00 CET – OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it has signed a world-wide, non-exclusive license agreement with QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA). Under this agreement, QIAGEN has licensed certain of OncoMethylome’s methylation technologies for use in certain of QIAGEN’s future products. These products will expand, among others, QIAGEN’s EpiTect product line. The agreement specifically covers the use of OncoMethylome’s patented Methylation-Specific PCR (MSP) technology, the most widely applied epigenetic technology, for the scientific research market. Under the terms of the agreement, QIAGEN will pay OncoMethylome an upfront fee plus royalties from future sales of products utilizing this technology. Other terms of the agreement were not disclosed.

Datum laatste update: 16 juli 2024